ImageneBio (IMA) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 16, 2026, to be held virtually, with voting on key proposals including director elections, auditor ratification, and an amended equity incentive plan.

• Only stockholders of record as of April 28, 2026, are eligible to vote; multiple voting methods are available including online, phone, and mail.

• The proxy statement details the merger between Ikena Oncology and Inmagene Biopharmaceuticals, resulting in the formation of ImageneBio, Inc.

Voting matters and shareholder proposals

• Proposal 1: Election of two Class II directors to serve until the 2029 Annual Meeting.

• Proposal 2: Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Proposal 3: Approval of an amendment to the 2025 Equity Incentive Plan, increasing authorized shares by 850,000 and modifying the annual share reserve calculation.

• Shareholder proposals for the 2027 Annual Meeting must be submitted by December 31, 2026, for inclusion in the proxy statement.

Board of directors and corporate governance

• Board consists of six members, divided into three classes with staggered three-year terms.

• Board leadership is separated, with Dr. Wang as non-executive Chair and Dr. Bonita as lead independent director.

• All committees (Audit, Compensation, Nominating and Corporate Governance) are composed of independent directors.

• Director nomination process emphasizes diversity, expertise, and independence; stockholders holding at least 3% for 24 months may recommend candidates.